Vstm3 is a member of the CD28 family and an important modulator of T‐cell function
暂无分享,去创建一个
T. Bukowski | J. Johnston | Wenfeng Xu | F. Ramsdell | S. Levin | C. Bucher | B. Blazar | J. Bilsborough | D. Ardourel | Craig D. Ostrander | J. West | L. Hebb | M. Rixon | K. Lewis | C. Brandt | Zeren Gao | B. Fox | J. Kuijper | E. Chadwick | E. Howard | A. Hammond | D. Taft | Kristen Bontadelli | A. Wolf | David W. Taft
[1] J. Anaya,et al. Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility to multiple autoimmune diseases. , 2010, Rheumatology.
[2] N. Stanietsky,et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity , 2009, Proceedings of the National Academy of Sciences.
[3] Eric Vivier,et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans , 2009, The Journal of experimental medicine.
[4] B. Harder,et al. Recombinant Soluble Human FcγR1A (CD64A) Reduces Inflammation in Murine Collagen-Induced Arthritis1 , 2009, The Journal of Immunology.
[5] L. Maier,et al. Autoimmunity risk alleles in costimulation pathways , 2009, Immunological reviews.
[6] M. Colonna,et al. A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC , 2009, European journal of immunology.
[7] T. Yasui,et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor , 2008, The Journal of experimental medicine.
[8] M. Colonna,et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors , 2008, The Journal of experimental medicine.
[9] E. Kremmer,et al. The murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1. , 2007, Biochemical and biophysical research communications.
[10] R. Parry,et al. Signalling to suit function: tailoring phosphoinositide 3-kinase during T-cell activation. , 2007, Trends in immunology.
[11] H. Ljunggren,et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. , 2007, Cancer research.
[12] S. Quezada,et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. , 2006, Current opinion in immunology.
[13] S. Honda,et al. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. , 2006, Blood.
[14] K. Murphy,et al. Differential Effects of B and T Lymphocyte Attenuator and Programmed Death-1 on Acceptance of Partially versus Fully MHC-Mismatched Cardiac Allografts1 , 2005, The Journal of Immunology.
[15] G. Freeman,et al. CD226 Is Specifically Expressed on the Surface of Th1 Cells and Regulates Their Expansion and Effector Functions1 , 2005, The Journal of Immunology.
[16] Darrell Conklin,et al. Gene finding for the helical cytokines , 2005, Bioinform..
[17] S. Honda,et al. Identification and characterization of murine DNAM-1 (CD226) and its poliovirus receptor family ligands. , 2005, Biochemical and biophysical research communications.
[18] A. Sharpe,et al. The B7/CD28 costimulatory family in autoimmunity , 2005, Immunological reviews.
[19] E. Lanino,et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). , 2005, Blood.
[20] L. Moretta,et al. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. , 2005, Molecular immunology.
[21] D. Louis,et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration , 2004, BMC Cancer.
[22] K. Irie,et al. Involvement of heterophilic trans‐interaction of Necl‐5/Tage4/PVR/CD155 with nectin‐3 in formation of nectin‐ and cadherin‐based adherens junctions , 2004, Genes to cells : devoted to molecular & cellular mechanisms.
[23] C. June,et al. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 , 2004, The Journal of Immunology.
[24] D. Bigner,et al. Poliovirus receptor CD155-targeted oncolysis of glioma. , 2004, Neuro-oncology.
[25] E. Devilard,et al. DNAM-1 and PVR Regulate Monocyte Migration through Endothelial Junctions , 2004, The Journal of experimental medicine.
[26] Lewis L Lanier,et al. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). , 2004, International immunology.
[27] M. Colonna,et al. Cutting Edge: CD96 (Tactile) Promotes NK Cell-Target Cell Adhesion by Interacting with the Poliovirus Receptor (CD155) , 2004, The Journal of Immunology.
[28] R. Förster,et al. Characterization and identification of Tage4 as the murine orthologue of human poliovirus receptor/CD155. , 2003, Biochemical and biophysical research communications.
[29] L. Moretta,et al. Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.
[30] J. Allison,et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 , 2003, Nature Immunology.
[31] H. Lassmann,et al. A comparative analysis of B cell‐mediated myelin oligodendrocyte glycoprotein‐experimental autoimmune encephalomyelitis pathogenesis in B cell‐deficient mice reveals an effect on demyelination , 2002, European journal of immunology.
[32] G. Freeman,et al. The B7–CD28 superfamily , 2002, Nature Reviews Immunology.
[33] T. Okazaki,et al. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[34] M. Denis,et al. Overexpression of the CD155 gene in human colorectal carcinoma , 2001, Gut.
[35] Don Foster,et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease , 2000, Nature.
[36] R. Perlmutter,et al. Distinct signals mediate maturation and allelic exclusion in lymphocyte progenitors. , 1999, Immunity.
[37] R. Karr,et al. CTLA-4-Fc treatment of ongoing EAE improves recovery, but has no effect upon relapse rate. Implications for the mechanisms involved in disease perpetuation , 1999, Journal of Neuroimmunology.
[38] M. Feldmann,et al. Prevention and amelioration of collagen‐induced arthritis by blockade of the CD28 co‐stimulatory pathway: requirement for both B7‐1 and B7‐2 , 1996, European journal of immunology.
[39] M. W. Flye,et al. Inhibition by CTLA4Ig of experimental allergic encephalomyelitis. , 1996, Journal of immunology.
[40] F J Grant,et al. Expression cloning and signaling properties of the rat glucagon receptor. , 1993, Science.
[41] E. Wimmer,et al. Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily , 1989, Cell.
[42] H. Clark,et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells , 2009, Nature Immunology.
[43] J. Haines,et al. The expanding genetic overlap between multiple sclerosis and type I diabetes , 2009, Genes and Immunity.
[44] J. Todd,et al. CD226 Gly307Ser association with multiple autoimmune diseases , 2009, Genes and Immunity.
[45] C. Ware,et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator , 2005, Nature Immunology.
[46] G. Freeman,et al. The B7 family revisited. , 2005, Annual review of immunology.
[47] G. Morahan,et al. T cell tolerance and autoimmunity. , 1997, Ciba Foundation symposium.